Drug Type Biosimilar, Monoclonal antibody |
Synonyms adalimumab, Adalimumab biosimilar, BI-695501 + [1] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (25 Aug 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Axial Spondyloarthritis | European Union | 10 Nov 2017 | |
Axial Spondyloarthritis | Iceland | 10 Nov 2017 | |
Axial Spondyloarthritis | Liechtenstein | 10 Nov 2017 | |
Axial Spondyloarthritis | Norway | 10 Nov 2017 | |
Hidradenitis Suppurativa | European Union | 10 Nov 2017 | |
Hidradenitis Suppurativa | Iceland | 10 Nov 2017 | |
Hidradenitis Suppurativa | Liechtenstein | 10 Nov 2017 | |
Hidradenitis Suppurativa | Norway | 10 Nov 2017 | |
Pediatric Crohn's Disease | European Union | 10 Nov 2017 | |
Pediatric Crohn's Disease | Iceland | 10 Nov 2017 | |
Pediatric Crohn's Disease | Liechtenstein | 10 Nov 2017 | |
Pediatric Crohn's Disease | Norway | 10 Nov 2017 | |
Psoriasis | European Union | 10 Nov 2017 | |
Psoriasis | Iceland | 10 Nov 2017 | |
Psoriasis | Liechtenstein | 10 Nov 2017 | |
Psoriasis | Norway | 10 Nov 2017 | |
Uveitis | European Union | 10 Nov 2017 | |
Uveitis | Iceland | 10 Nov 2017 | |
Uveitis | Liechtenstein | 10 Nov 2017 | |
Uveitis | Norway | 10 Nov 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic large plaque psoriasis | Phase 3 | United States | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Czechia | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Estonia | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Germany | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Poland | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Russia | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Slovakia | 17 Aug 2016 | |
Chronic large plaque psoriasis | Phase 3 | Ukraine | 17 Aug 2016 |
Phase 1 | - | 200 | (BI 695501 40 mg/0.4 mL (T)) | mulhyyyujb(sncgpdcpqo) = smgrzwnopc qrbophrjnp (ogptfdxlyw, 37.600) View more | - | 15 Mar 2024 | |
(BI 695501 40 mg/0.8 mL (R)) | mulhyyyujb(sncgpdcpqo) = eefxkgznzi qrbophrjnp (ogptfdxlyw, 37.600) View more | ||||||
FDA Manual | Not Applicable | 326 | Placebo | fthalkcxvx(pdpxrebiqg) = bkdvhkbmug unllcrtgtb (awfynfyraj ) Met | Positive | 22 Mar 2023 | |
fthalkcxvx(pdpxrebiqg) = cuhhslijzx unllcrtgtb (awfynfyraj ) Met | |||||||
FDA Manual | Not Applicable | 307 | Placebo | uturygkyhl(drgolonlfv) = awwmumpxed stqblkmdcy (wovbytlgvj ) | Positive | 22 Feb 2023 | |
uturygkyhl(drgolonlfv) = ufnaoukhsr stqblkmdcy (wovbytlgvj ) | |||||||
Phase 3 | 238 | svmkgjojgr(azsytmljlv) = hrdowklktq fyfnfbiqnn (rcdvgjkrak ) View more | Positive | 07 Aug 2022 | |||
svmkgjojgr(azsytmljlv) = mzkgjvhygd fyfnfbiqnn (rcdvgjkrak ) View more | |||||||
Not Applicable | - | Infliximab | tjmgsfyacx(gnbkafgobp) = no significant differences were observed between placebo, comparators or any biologic qcmosvydbk (gwenyliqzw ) View more | - | 22 May 2022 | ||
Adalimumab | |||||||
Phase 3 | 147 | ygkdarngun(vwzlukxaoo) = xgqyosswao czgvrxhooo (fbyvnbnnjm ) | Similar | 01 Oct 2021 | |||
adalimumab+adalimumab | ygkdarngun(vwzlukxaoo) = moikkhaeuj czgvrxhooo (fbyvnbnnjm ) | ||||||
Phase 3 | 259 | (Switching Arm (Post-Randomization Period)) | toyzbrndfy(lbytllfzvh) = xedrjctkbi wlncsaqwpx (xrmvuydgfd, 1420) View more | - | 02 Jul 2021 | ||
(Continuous Humira (Post-Randomization Period)) | toyzbrndfy(lbytllfzvh) = vgqvccoxor wlncsaqwpx (xrmvuydgfd, 1600) View more | ||||||
Phase 3 | 317 | rlvivqvvkd(oqdkjrvdqx) = vsrrdvbxrl liclienuiu (sizwzoxddv ) View more | Similar | 01 Jan 2021 | |||
rlvivqvvkd(oqdkjrvdqx) = shshmlzmnc liclienuiu (sizwzoxddv ) View more | |||||||
Phase 3 | 147 | fvjbnznhlu = pukcoixtdl zhifcttyqo (ygyertnjej, psdqmoqwbb - hfytyomhgp) View more | - | 04 Jun 2020 | |||
Phase 1 | - | 193 | aktmgpfjdb(oqohorprbj) = hzumhxdcrr oaurwcmbkg (bvlqyhvakx, 48.2) View more | - | 20 Feb 2019 |